Outcome of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Hematopoietic Cell Transplant Recipients Receiving Aerosolized Ribavirin: Significance of Stem Cell Source and Oxygen Requirement

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 4, 2013, Pages 589-596

  Seo, Sachiko ^a   Campbell, Angela P ^a,b,c   Xie, Hu ^a   Chien, Jason W ^a,d   Leisenring, Wendy M ^a,e   Englund, Janet A ^a,b,c   Boeckh, Michael ^a,e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d GILEAD SCIENCES INC   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hematopoietic cell transplantation; Lower respiratory tract disease; Palivizumab; Pulmonary function; Respiratory syncytial virus

Indexed keywords

IMMUNOGLOBULIN; PALIVIZUMAB; RIBAVIRIN;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HAZARD RATIO; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; OXYGEN CONSUMPTION; PERIPHERAL BLOOD STEM CELL; RESPIRATORY FAILURE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT DISEASE; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AEROSOLS; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RIBAVIRIN; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84875486452     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.12.019     Document Type: Article

References (39)

1. Martino R., Porras R.P., Rabella N., et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 2005, 11:781-796.
2. Nichols W.G., Gooley T., Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001, 7(Suppl):11S-15S.
3. Khanna N., Widmer A.F., Decker M., et al. Respiratory syncytial virus infection in patients with hematological diseases: Single-center study and review of the literature. Clin Infect Dis 2008, 46:402-412.
4. McCarthy A.J., Kingman H.M., Kelly C., et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. Bone Marrow Transplant 1999, 24:1315-1322.
5. Erard V., Chien J.W., Kim H.W., et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis 2006, 193:1619-1625.
6. Shah J.N., Chemaly R.F. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011, 117:2755-2763.
7. Boeckh M., Englund J., Li Y., et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007, 44:245-249.
8. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
9. Community-acquired respiratory viruses. Am J Transplant 2004, 4(Suppl 10):105-109.
10. Upton A., Kirby K.A., Carpenter P., et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007, 44:531-540.
11. de Fontbrune F.S., Robin M., Porcher R., et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007, 45:1019-1024.
12. Chemaly R.F., Torres H.A., Munsell M.F., et al. An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis 2012, 206:1367-1371.
13. Boeckh M., Berrey M.M., Bowden R.A., et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001, 184:350-354.
14. American Thoracic Society Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991, 144:1202-1218.
15. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
16. Williams K.M., Chien J.W., Gladwin M.T., Pavletic S.Z. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009, 302:306-314.
17. Au B.K., Au M.A., Chien J.W. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1072-1078.
18. Storek J., Dawson M.A., Storer B., et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001, 97:3380-3389.
19. Talmadge J.E., Reed E., Ino K., et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 1997, 19:161-172.
20. Ottinger H.D., Beelen D.W., Scheulen B., et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996, 88:2775-2779.
21. Jacobson C.A., Turki A.T., McDonough S.M., et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:565-574.
22. D'Arena G., Musto P., Cascavilla N., et al. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features. Haematologica 1998, 83:197-203.
23. Komanduri K.V., St John L.S., de Lima M., et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007, 110:4543-4551.
24. Ruggeri A., Peffault de Latour R., Carmagnat M., et al. Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases. Transplant Infect Dis 2011, 13:456-465.
25. Banna G.L., Aversa S.M., Cattelan A.M., et al. Respiratory syncytial virus-related pneumonia after stem cell transplantation successfully treated with palivizumab and steroid therapy. Scand J Infect Dis 2004, 36:155-157.
26. McCoy D., Wong E., Kuyumjian A.G., et al. Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline. Transplant Infect Dis 2011, 13:117-121.
27. Tsitsikas D.A., Oakervee H., Cavenagh J.D., et al. Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience. Br J Haematol 2009, 146:574-576.
28. Chavez-Bueno S., Mejias A., Merryman R.A., et al. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatric Infect Dis J 2007, 26:1089-1093.
29. Ottolini M.G., Curtis S.R., Mathews A., et al. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant 2002, 29:117-120.
30. Malley R., DeVincenzo J., Ramilo O., et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998, 178:1555-1561.
31. Simoes E.A., Groothuis J.R., Carbonell-Estrany X., et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007, 151:34-42.
32. Carbonell-Estrany X., Simoes E.A., Dagan R., et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010, 125:e35-e51.
33. Lagos R., DeVincenzo J.P., Munoz A., et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J 2009, 28:835-837.
34. Octavio RSJ, Wang K, Jensen K, et al. Motavizumab treatment of children hospitalized with RSV lower respiratory tract infection does not decrease viral load or severity of illness. Presented at the 8th annual Respiratory Syncytial Virus Symposium, Santa Fe, New Mexico, 2012.
35. Magnusson J., Westin J., Andersson L.M. The impact of viral respiratory tract infections on long-term morbidity and mortality following lung transplantation: a retrospective cohort study using a multiplex PCR panel. Transplantation 2013, 95:383-388.
36. Vu D.L., Bridevaux P.O., Aubert J.D., et al. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant 2011, 11:1071-1078.
37. Khalifah A.P., Hachem R.R., Chakinala M.M., et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004, 170:181-187.
38. Gottlieb J., Schulz T.F., Welte T., et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 2009, 87:1530-1537.
39. Nakaseko C., Ozawa S., Sakaida E., et al. Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol 2011, 93:375-382.